Carasent AB (publ)

LSE:0H9M Stock Report

Market Cap: NOK 1.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Carasent Valuation

Is 0H9M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0H9M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
NOK 33.67
Fair Value
38.8% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: 0H9M (NOK20.6) is trading below our estimate of fair value (NOK33.67)

Significantly Below Fair Value: 0H9M is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0H9M?

Key metric: As 0H9M is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0H9M. This is calculated by dividing 0H9M's market cap by their current revenue.
What is 0H9M's PS Ratio?
PS Ratio5.8x
SalesNOK 264.80m
Market CapNOK 1.53b

Price to Sales Ratio vs Peers

How does 0H9M's PS Ratio compare to its peers?

The above table shows the PS ratio for 0H9M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
INS Instem
3.2x11.4%UK£199.6m
OPT Optima Health
1.2x4.8%UK£124.7m
IUG Intelligent Ultrasound Group
4.2xn/aUK£41.7m
CRW Craneware
4.7x8.1%UK£738.9m
0H9M Carasent
5.8x18.6%NOK 1.5b

Price-To-Sales vs Peers: 0H9M is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (3.6x).

Price to Sales Ratio vs Industry

How does 0H9M's PS Ratio compare vs other companies in the European Healthcare Services Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
0H9M 5.8xIndustry Avg. 2.3xNo. of Companies10PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0H9M is expensive based on its Price-To-Sales Ratio (5.8x) compared to the European Healthcare Services industry average (2.3x).

Price to Sales Ratio vs Fair Ratio

What is 0H9M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0H9M PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0H9M's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0H9M forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
NOK 26.00
0%
4.2%NOK 27.00NOK 24.50n/a3
Jan ’26n/a
NOK 26.00
0%
4.2%NOK 27.00NOK 24.50n/a3
Dec ’25NOK 20.60
NOK 26.00
+26.2%
4.2%NOK 27.00NOK 24.50n/a3
Nov ’25NOK 19.85
NOK 26.75
+34.8%
0.9%NOK 27.00NOK 26.50n/a2
Oct ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
Sep ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
Aug ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
Jul ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
Jun ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
May ’25NOK 14.33
NOK 25.75
+79.7%
2.9%NOK 26.50NOK 25.00n/a2
Apr ’25NOK 11.17
NOK 26.50
+137.2%
5.7%NOK 28.00NOK 25.00n/a2
Mar ’25NOK 11.26
NOK 26.50
+135.4%
5.7%NOK 28.00NOK 25.00n/a2
Feb ’25n/a
NOK 26.50
0%
5.7%NOK 28.00NOK 25.00n/a2
Jan ’25n/a
NOK 26.50
0%
5.7%NOK 28.00NOK 25.00n/a2
Dec ’24NOK 10.60
NOK 26.50
+150.0%
5.7%NOK 28.00NOK 25.00NOK 20.602
Nov ’24NOK 13.32
NOK 29.00
+117.7%
3.4%NOK 30.00NOK 28.00NOK 19.852
May ’24NOK 15.78
NOK 37.00
+134.5%
5.4%NOK 39.00NOK 35.00NOK 14.332
Apr ’24NOK 16.05
NOK 37.00
+130.5%
5.4%NOK 39.00NOK 35.00NOK 11.172
Mar ’24NOK 16.60
NOK 37.00
+122.9%
5.4%NOK 39.00NOK 35.00NOK 11.262
Feb ’24NOK 16.14
NOK 38.00
+135.4%
2.6%NOK 39.00NOK 37.00n/a2
Jan ’24NOK 16.37
NOK 38.00
+132.1%
2.6%NOK 39.00NOK 37.00n/a2
Analyst Price Target
Consensus Narrative from 3 Analysts
NOK 25.38
Fair Value
18.8% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/05 15:46
End of Day Share Price 2024/11/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carasent AB (publ) is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Commissioned Research
Ole-Andreas KrohnDNB Markets
Christoffer BjørnsenDNB Markets